Markets:

Overview

News

Currencies

International

Treasuries

Apellis Pharmaceuticals, Inc. - Common Stock (NQ:APLS)

22.58 -0.47 (-2.04%)

Streaming Delayed Price Updated: 4:00 PM EST, Jan 30, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Apellis Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Apellis Pharmaceuticals Stock Shows Rising Relative Strength ↗

April 04, 2022

Apellis Pharmaceuticals stock saw a welcome improvement to its Relative Strength (RS) Rating on Monday, rising from 87 to 91.

Via Investor's Business Daily

The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL ↗

March 24, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

12 Health Care Stocks Moving In Wednesday's After-Market Session ↗

March 23, 2022

Gainers Greenwich LifeSciences (NASDAQ:GLSI) stock moved upwards by 9.6% to $23.84 during Wednesday's after-market session. The market value of their outstanding shares is at $312.8 million. As per the...

Via Benzinga

Why Apellis Pharmaceuticals Stock Is Falling After Hours ↗

March 23, 2022

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading lower in Wednesday's after-hours session after the company announced a proposed public offering of $300 million...

Via Benzinga

Apellis' Pegcetacoplan Showed Continuous, Meaningful Effects At Month 18 In Geographic Atrophy Studies ↗

March 16, 2022

Via Benzinga

Earnings Scheduled For February 28, 2022 ↗

February 28, 2022

Companies Reporting Before The Bell • Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter. • Praxis Precision Medicine (...

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

January 11, 2022

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Apellis Pharma Nears Breakout As Biotech Plots Its Blockbuster Filing ↗

March 16, 2022

If approved, this would be the company's second drug to hit the U.S. market.

Via Investor's Business Daily

Here's Why Apellis Pharmaceuticals Shares Are Rising ↗

March 16, 2022

Apellis Pharmaceuticals Inc (NASDAQ: APLS) shares are trading higher by 8.6% at $43.49 after the company announced Pegcetacoplan showed continuous and clinically meaningful effects at month 18 in Phase...

Via Benzinga

The Daily Biotech Pulse: Pfizer-BioNTech Apply For Authorization Of 3rd Booster Shot, Sanofi-Seagen Strike Cancer Therapy Pact, Iovance Gets Nod For Cancer Study ↗

March 16, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Expert Ratings For Apellis Pharmaceuticals ↗

March 07, 2022

Over the past 3 months, 4 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:APLS) stock. These analysts are typically employed by large Wall Street banks...

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

March 07, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish...

Via Benzinga

Apellis Pharmaceuticals: Q4 Earnings Insights ↗

February 28, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) reported its Q4 earnings results on Monday, February 28, 2022 at 04:00 PM. Here's what investors need to know about the announcement....

Via Benzinga

Apellis Pharmaceuticals's Earnings Outlook ↗

February 25, 2022

Apellis Pharmaceuticals (NASDAQ:APLS) is set to give its latest quarterly earnings report on Monday, 2022-02-28. Here's what investors need to know before the announcement....

Via Benzinga

Apellis - Sobi's Pegcetacoplan Wins European Approval For Rare Blood Disorder ↗

December 15, 2021

The European Commission has approved Swedish Orphan Biovitrum AB (OTC: BIOVF) - Apellis Pharmaceuticals Inc's (NASDAQ: APLS) Aspaveli (pegcetacoplan...

Via Benzinga

The Daily Biotech Pulse: Lilly Raises Guidance, Medtronic Gets FDA Warning Letter, Decision Day For Calliditas, Genenta IPO ↗

December 15, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Vir Biotech Says COVID-19 Antibody Treatment Effective Against Omicron...

Via Benzinga

What 9 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

December 08, 2021

Within the last quarter, Apellis Pharmaceuticals (NASDAQ:APLS) has observed...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For December 8, 2021 ↗

December 08, 2021

Upgrades According to Deutsche Bank, the prior rating for Goodyear Tire & Rubber Co (NASD...

Via Benzinga

Analyst Ratings For Apellis Pharmaceuticals ↗

November 29, 2021

Over the past 3 months, 8 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For November 29, 2021 ↗

November 29, 2021

Upgrades According to Odeon Capital, the prior rating for Wells Fargo & Co (NYSE:

Via Benzinga

The Daily Biotech Pulse: Kezar Jumps On Data, Biogen R&D Chief To Retire, Molecular Partners Wilts On COVID Trial Disappointment ↗

November 16, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Kezar Life Sciences Reports Positive Interim Phase 2 Data For Lupus Nephritis...

Via Benzinga

12 Health Care Stocks Moving In Monday's After-Market Session ↗

November 15, 2021

Gainers Kezar Life Sciences (NASDAQ:KZR) s...

Via Benzinga

Where Apellis Pharmaceuticals Stands With Analysts ↗

November 09, 2021

Analysts have provided the following ratings for Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

Cramer Likes DraftKings, Skyworks, And These Automakers ↗

October 07, 2021

On CNBC's "Mad Money Lightning Rou...

Via Benzinga

Better Pharmaceutical Stock: Apellis or Novartis? ↗

September 15, 2021

The pharmaceutical industry is expected to remain in the limelight as companies race to develop new medicines catering to mild diseases and critical ailments.

Via Talk Markets

Raymond James Upgraded This Biopharma Stock And Sees 44% Upside ↗

September 13, 2021

Raymond James has upgraded NGM Biopharmaceuticals Inc (NASDAQ:

Via Benzinga

60 Biggest Movers From Friday ↗

September 13, 2021

Gainers IVERIC bio, Inc. (NASDAQ: ISEE) shares surged 62.5% to close at $14.12 on Friday after Apellis Pharmaceuticals reported results from its Phase 3 DERBY and OAKS studies in...

Via Benzinga

Mid-Afternoon Market Update: Dow Slides Over 100 Points; Echo Global Logistics Shares Spike Higher ↗

September 10, 2021

Toward the end of trading Friday, the Dow traded down 0.31% to 34,772.74 while the NASDAQ fell 0.27% to 15,207.42. The S&P also fell, dropping 0.28% to 4,480.86. The U.S. has...

Via Benzinga

Topics Stocks

What 11 Analyst Ratings Have To Say About Apellis Pharmaceuticals ↗

September 10, 2021

Over the past 3 months, 11 analysts have published their opinion on Apellis Pharmaceuticals (NASDAQ:

Via Benzinga

8 Health Care Stocks With Unusual Options Alerts In Today's Session ↗

September 10, 2021

This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.